A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared ...

A large clinical trial in China (HARMONi-6) found that a new immunotherapy drug, ivonescimab, may help patients with advanced ...

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, ...

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various ...

Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous ...

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy. Patients with previously untreated advanced squamous non-small cell lung ...

A lung cancer drug reduced the risk of death by 34% in a late-stage trial, in the latest sign of China’s pharmaceutical ...

New dual-action drug a ‘promising step forward’ for patients with hard-to-treat lung cancer - Experts have described the ...